A RANDOMIZED DOUBLE BLIND CLINICAL TRIAL IN FAMOTIDINE ADJUVANT THERAPY IN SCHIZOPHRENIA

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

FARZIN D.; HOSSEINI SEYED HAMZEH; SHAFAAT A.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: IRANIAN JOURNAL OF MEDICAL SCIENCES (IJMS) Year:2005 | Volume:30 | Issue:2 Page(s): 59-62

Download Full-Text

View:

344

Download:

224

Cites:

Information Journal Paper

Title

A RANDOMIZED DOUBLE BLIND CLINICAL TRIAL IN FAMOTIDINE ADJUVANT THERAPY IN SCHIZOPHRENIA

Author(s)

FARZIN D. | HOSSEINI SEYED HAMZEH | SHAFAAT A. | Issue Writer Certificate

Keywords

FAMOTIDINE/ H2 RECEPTOR ANTAGONISTS / SCHIZOPHRENIA/ NEUROLEPTICS

Abstract

Background: About 40%-60% of schizophrenic patients are resistant to ordinary treatment, which result from interference with different neurotransmitter systems in the process of disease. The aim of present study was to determine the effect of famotidine on several symptoms of schizophrenia which was nonresponsive to neuroleptic treatment. Methods: 30 schizophrenic patients previously nonresponsive to ordinary treatment were categorized into two groups. Famotidine group received perphenazine plus famotidine and placebo group received perfenazine plus a placebo. Patients in both groups were followed for 6 weeks and assessed by the positive and negative symptom scales (PANSS) at weeks 0, 2 and 6 of the treatment. Results: Both groups were similar in terms of positive and negative symptoms. In the placebo group, the total scores of PANSS (severity of the disease) did not change significantly. However, based on the total scores of PANSS, there was a significant difference between both famotidine and placebo groups at the end of sixth week (P<0.05). In terms of general psychopathology scale and aggressive risk, there was also a significant difference between both famotidine and control groups at the end of sixth week. Conclusion: Famotidine can improve the symptoms of schizophrenic patients who were not responsive to neuroleptics.

Cites

No record.

References

No record.

Cite

APA: Copy

FARZIN, D., HOSSEINI, SEYED HAMZEH, & SHAFAAT, A.. (2005). A RANDOMIZED DOUBLE BLIND CLINICAL TRIAL IN FAMOTIDINE ADJUVANT THERAPY IN SCHIZOPHRENIA. IRANIAN JOURNAL OF MEDICAL SCIENCES (IJMS), 30(2), 59-62. SID. https://sid.ir/paper/275867/en

Vancouver: Copy

FARZIN D., HOSSEINI SEYED HAMZEH, SHAFAAT A.. A RANDOMIZED DOUBLE BLIND CLINICAL TRIAL IN FAMOTIDINE ADJUVANT THERAPY IN SCHIZOPHRENIA. IRANIAN JOURNAL OF MEDICAL SCIENCES (IJMS)[Internet]. 2005;30(2):59-62. Available from: https://sid.ir/paper/275867/en

IEEE: Copy

D. FARZIN, SEYED HAMZEH HOSSEINI, and A. SHAFAAT, “A RANDOMIZED DOUBLE BLIND CLINICAL TRIAL IN FAMOTIDINE ADJUVANT THERAPY IN SCHIZOPHRENIA,” IRANIAN JOURNAL OF MEDICAL SCIENCES (IJMS), vol. 30, no. 2, pp. 59–62, 2005, [Online]. Available: https://sid.ir/paper/275867/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops